The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Predict the Presence of Amyloid with Cognivue Clarity.

Journal: Neurology and therapy
Published Date: Apr 7, 2025

Abstract

INTRODUCTION: At the present time, clinical detection of individuals who have amyloid in their brain is not possible without expensive biomarkers. The objective of the study was to test whether Cognivue Clarity can differentiate True Controls, preclinical Alzheimer's disease (pAD), mild cognitive impairment (MCI) due to Alzheimer's disease (MCI-AD), AD, and MCI and dementia due to non-AD etiologies enrolled in the Bio-Hermes Study.

Authors

  • James E Galvin
    Department of Neurology, Comprehensive Center for Brain Health, University of Miami Miller School of Medicine, Miami, FL, United States.
  • Michael J Kleiman
    Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Heather M Harris
    Cognivue, Inc, 7911 Rae Blvd, Victor, NY, 14564, USA.
  • Paul W Estes
    Cognivue, Inc, 7911 Rae Blvd, Victor, NY, 14564, USA.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals